Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma

被引:45
作者
Castellón, E
Clementi, M
Hitschfeld, C
Sánchez, C
Benítez, D
Sáenz, L
Contreras, H
Huidobro, C
机构
[1] Univ Chile, Fac Med, Physiol & Biophys Program, Inst Biomed Sci, Santiago 6530499, Chile
[2] Univ Chile, Dept Urol, Clin Hosp JJ Aguirre, Santiago, Chile
关键词
GnRH analogs; GnRH receptor; prostate cancer; proliferation; apoptosis; primary cell culture;
D O I
10.1080/07357900600629591
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Contradictory data have been reported regarding the effect of GnRH agonists and antagonists on cell growth and survival, using prostate cancer-derived cell lines expressing either endogenous or exogenous GnRH receptors. We addressed the issue studying the effect of leuprolide (agonist) and cetrorelix (antagonist) on cell growth, apoptosis and GnRH receptor expression using a primary cell coculture system. Also, binding characteristics of prostate GnRH receptor in this culture system are described. Epithelial and stromal cells were obtained from prostate adenocarcinoma samples and cocultured in a bicameral system. Expression of GnRH receptors was evaluated by semiquantitative RT-PCR (transcript level) and Western blot (protein level). Cell growth was estimated by MTT method and apoptosis by DNA fragmentation using COMET assay. Saturation and competition binding studies were carried out using 125 I-GnRH as radioligand. GnRH receptors from cell cultures of prostate cancer exhibited a single class of binding sites with a Kd of 1.11 0.28 nM and a Bmax of 2.81 0.37 pmol/mg of membrane protein for GnRH. Leuprolide and cetrorelix showed no effect on GnRH receptor expression. Both analogues showed a significant reduction in cell growth rate and an increase in DNA-fragmented cell number. These effects were dependent on the analogue concentrations (from 5-20 ng/mL). Considering that the culture system used in this work represents more closely the in vivo conditions of tumor cells than metastatic derived cell lines, we conclude that GnRH analogues have a significant inhibitory effect on cell viability of cells expressing GnRH receptors. In addition, GnRH receptors expressed in tumor prostatic cells seem not discriminate between agonist and antagonist, both analogues activating these receptors. Also, leuprolide and cetrorelix treatments did not influence GnRH receptor expression in our culture system. These differences with pituitary receptors may be explained by differences in affinity, transduction mechanism and molecular context in prostatic tissue.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 37 条
[1]
BHERE H, 1994, CLIN ENDOCRINOL OXF, V40, P241
[2]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]
CARMICHAEL J, 1987, CANCER RES, V47, P943
[4]
Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma [J].
Castellón, E ;
Venegas, K ;
Sáenz, L ;
Contreras, H ;
Huidobro, C .
INTERNATIONAL JOURNAL OF ANDROLOGY, 2005, 28 (01) :39-46
[5]
Chatzaki E, 1996, CANCER RES, V56, P2059
[6]
THE ENDOCRINOLOGY AND DEVELOPMENTAL BIOLOGY OF THE PROSTATE [J].
CUNHA, GR ;
DONJACOUR, AA ;
COOKE, PS ;
MEE, S ;
BIGSBY, RM ;
HIGGINS, SJ ;
SUGIMURA, Y .
ENDOCRINE REVIEWS, 1987, 8 (03) :338-362
[7]
Role of the stromal microenvironment in carcinogenesis of the prostate [J].
Cunha, GR ;
Hayward, SW ;
Wang, YZ ;
Ricke, WA .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (01) :1-10
[8]
DONDI D, 1994, CANCER RES, V54, P4091
[9]
RECEPTORS FOR LUTEINIZING-HORMONE-RELEASING HORMONE, SOMATOSTATIN, PROLACTIN, AND EPIDERMAL GROWTH-FACTOR IN RAT AND HUMAN-PROSTATE CANCERS AND IN BENIGN PROSTATE HYPERPLASIA [J].
FEKETE, M ;
REDDING, TW ;
COMARUSCHALLY, AM ;
PONTES, JE ;
CONNELLY, RW ;
SRKALOVIC, G ;
SCHALLY, AV .
PROSTATE, 1989, 14 (03) :191-208
[10]
Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus [J].
Franklin, J ;
Hislop, J ;
Flynn, A ;
McArdle, CA .
JOURNAL OF ENDOCRINOLOGY, 2003, 176 (02) :275-284